Big Molecule Watch
February 9, 2021

Clinical Updates

As described below, Adocia, Cue Biopharma, and Eucure Biopharma each recently announced clinical updates with regards to their biologic product candidates or combination therapies.

Adocia, a clinical-stage biotechnology company headquartered in France, reported positive results from a clinical pharmacology study using its proprietary BioChaperone® (BC) ultra-rapid prandial insulin formulation.  The study compared two BC Lispro formulations employing insulin lispro from two different sources, an insulin lispro biosimilar from Tonghua Dongbao (THDB) and the brand, Humalog®, from Eli Lilly.  The BC Lispro (THDB) formulation demonstrated similar pharmacodynamic and pharmacokinetic properties to the BC Lispro Humalog® formulation.

Cue Biopharma, Inc., based in Cambridge, Massachusetts, announced that the first patient was dosed in a Phase 1 dose escalation clinical trial of CUE-101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).  CUE-101 is a fusion protein biologic designed to target and activate antigen-specific T cells to fight HPV-driven cancers.  CUE-101 is being evaluated in combination with KEYTRUDA® for treatment for human papilloma virus positive recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSCC).

Beijing based Eucure Biopharma also announced that YH003, an investigational anti-CD40 antibody, demonstrated anti-tumor activity in subjects with advanced solid tumors when combined with Junshi Biosciences’ anti-PD-1 antibody Toripalimab (TUOYI®).  Toripalimab is the first anti-PD-1 monoclonal antibody to obtain a marketing approval in China.

The post Clinical Updates appeared first on Big Molecule Watch.